Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.

Fischl MA, Ribaudo HJ, Collier AC, Erice A, Giuliano M, Dehlinger M, Eron JJ Jr, Saag MS, Hammer SM, Vella S, Morse GD, Feinberg JE, Demeter LM, Eshleman SH; Adult AIDS Clinical Trials Group 388 Study Team.

J Infect Dis. 2003 Sep 1;188(5):625-34. Epub 2003 Aug 15. Erratum in: J Infect Dis. 2003 Oct 1;188(7):1083.

PMID:
12934177
2.

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.

Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM.

N Engl J Med. 1999 Dec 16;341(25):1865-73.

3.

HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.

Demeter LM, Ribaudo HJ, Erice A, Eshleman SH, Hammer SM, Hellmann NS, Fischl MA; AIDS Clinical Trials Group Protocol 388.

Clin Infect Dis. 2004 Aug 15;39(4):552-8. Epub 2004 Jul 30.

PMID:
15356820
4.

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.

Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW; AIDS Clinical Trials Group 398 Study Team.

JAMA. 2002 Jul 10;288(2):169-80.

PMID:
12095381
5.

Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection.

Tashima K, Staszewski S, Nelson M, Rachlis A, Skiest D, Stryker R, Bessen L, Overfield S, Ruiz N, Wirtz V.

AIDS. 2008 Jan 11;22(2):275-9. Erratum in: AIDS. 2011 Feb 20;25(4):545.

PMID:
18097230
6.

Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.

Saah AJ, Haas DW, DiNubile MJ, Chen J, Holder DJ, Rhodes RR, Shivaprakash M, Bakshi KK, Danovich RM, Graham DJ, Condra JH.

J Infect Dis. 2003 Apr 1;187(7):1157-62. Epub 2003 Mar 19.

PMID:
12660932
7.

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.

Albrecht MA, Bosch RJ, Hammer SM, Liou SH, Kessler H, Para MF, Eron J, Valdez H, Dehlinger M, Katzenstein DA; AIDS Clinical Trials Group 364 Study Team.

N Engl J Med. 2001 Aug 9;345(6):398-407.

8.

Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).

Vibhagool A, Cahn P, Schechter M, Smaill F, Soto-Ramirez L, Carosi G, Montroni M, Pharo CE, Jordan JC, Thomas NE, Pearce G.

Curr Med Res Opin. 2004 Jul;20(7):1103-14.

PMID:
15265255
9.

Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.

Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, Bower M, Johnson MA, Gazzard BG.

AIDS. 2002 Jan 4;16(1):53-61.

PMID:
11741163
10.

Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.

Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttola V, Pollard RB, Merigan TC, Hirsch MS, George AL Jr, Donahue JP, Kim RB.

J Infect Dis. 2005 Dec 1;192(11):1931-42. Epub 2005 Nov 1.

PMID:
16267764
12.

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E; M98-863 Study Team.

N Engl J Med. 2002 Jun 27;346(26):2039-46.

13.

Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children.

van Rossum AM, Bergshoeff AS, Fraaij PL, Hugen PW, Hartwig NG, Geelen SP, Wolfs TF, Weemaes CM, De Groot R, Burger DM.

Pediatr Infect Dis J. 2002 Aug;21(8):743-7.

PMID:
12192162
14.

Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.

Cahn P, Vibhagool A, Schechter M, Soto-Ramirez L, Carosi G, Smaill F, Jordan JC, Pharo CE, Thomas NE, Steel HM.

Curr Med Res Opin. 2004 Jul;20(7):1115-23.

PMID:
15265256
15.

Antiretroviral rounds. When success is a pain.

Bartlett JG, del Rio C.

AIDS Clin Care. 2001 Aug;13(8):74-5. No abstract available.

PMID:
11547461
16.

[HIV infection: DuPont Pharma presents the results of its antiretroviral agent].

[No authors listed]

Allerg Immunol (Paris). 1998 Apr;30(4):123-4. French. No abstract available.

PMID:
9631694
17.

Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens.

Barreiro P, Oller V, Soriano V, Nuñez M, Rodríguez-Rosado R, González-Lahoz J.

J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):391-2. No abstract available.

PMID:
11317086
19.

Update on antivirals.

[No authors listed]

Proj Inf Perspect. 1997 Nov;(23):8-11.

PMID:
11365381

Supplemental Content

Support Center